Abstract c-Aminobutyric acid type A receptors (GABA A -Rs) are considered to be the primary molecular targets of injectable anesthetics such as propofol, etomidate and the neurosteriod, alphaxalone. A number of studies have sought to understand the specific GABA A -R subtypes involved in the mechanism of action of these three drugs. Here, we investigated the role of a4-subunit containing GABA A -Rs in the neurobehavioral responses to these drugs. Drug responses in a4 subunit knockout (KO) mice were compared to wild type (WT) littermate controls. While etomidate and propofol are currently used as injectable anesthetics, alphaxalone belongs to the class of neurosteroid drugs having anesthetic effects. Low dose effects of etomidate and alphaxalone were studied using an open field assay. The moderate and high dose effects of all three anesthetics were measured using the rotarod and loss of righting reflex assays, respectively. The locomotor stimulatory effect of alphaxalone was reduced significantly in a4 KO mice compared to WT controls. Neither the low dose sedating effect of etomidate, nor the moderate/high dose effect of any of the drugs differed between genotypes. These results suggest that a4 subunit-containing GABA ARs are required for the low dose, locomotor stimulatory effect of alphaxalone but are not required for the sedating effect of etomidate or the moderate/high dose effects of etomidate, propofol or alphaxalone on motor ataxia and loss of righting reflex.
Background
Despite their wide clinical usage, the mechanism of action of injectable anesthetic drugs such as etomidate, propofol and alphaxalone is not completely known. Of prime importance for mediating the effects of anesthetics are c-aminobutyric acid type A receptors (GABA A -Rs). GABA A -Rs are pentameric ligand gated chloride ion channels that mediate the majority of inhibitory neurotransmission in the brain. A functional receptor is assembled from amongst 19 distinct subunits, a1-6, b1-3, c1-3, d, e, p, h and q1-3 [1] . Most GABA A -Rs are composed of 2a, 2b and a c or d subunit [2, 3] . This diversity in GABA A -R subunit composition results in substantial anatomical, functional and pharmacological heterogeneity. The contributions of particular GABA A -R subtypes to the behavioral endpoints produced by injectable anesthetics are gradually being understood-largely through studies using genetically engineered mouse lines. For example, GABA A -R N265M b3 subunit knockin (KI) studies revealed that b3-containing receptors are required for etomidate and propofol-induced immobility, respiratory depression and hypnosis (in part) [4, 5] . Similar studies on b2 N265S KI mice revealed that b2-containing GABA A -Rs mediate etomidate and propofol-induced sedation, hypothermia, heart rate depression, and hypnosis [6] [7] [8] . These results are consistent with the studies of b2 and b3 knockout (KO) mice [9] [10] [11] . Similarly, GABA A -R d subunit KO mice revealed that d-containing receptors are required for many neurosteroidinduced behavioral effects [12] .
However, the role of the obligate a subunits partnering with b and d subunits in the mechanisms of anesthetic action is largely unknown. d subunit containing receptors are mainly extrasynaptic and are uniquely sensitive to low levels of GABA [13] [14] [15] . Because they are sensitive to non-saturating levels of GABA, extrasynaptic receptors are capable of greater potentiation in the presence of anesthetics [16] . In their extrasynaptic location, d subunits pair with b2 or b3 subunits and a4 or a6 subunits [12, [17] [18] [19] . Thus, a4bd and a6bd receptor combinations are good candidates for modulation by anesthetics like etomidate and propofol.
While a6-containing receptors show restricted localization in the cerebellum, a4-containing receptors are robustly expressed in brain regions that likely contribute to anesthetic-induced behaviors such as the thalamus, hippocampus, and cortex. On the subject of endogenous modulators, studies have also shown that fluctuating levels of endogenous steroids such as that encountered during the estrous cycle, pregnancy or stress influence the levels of a4-d containing receptors [20, 21] . Further, deficiency in GABAergic signaling during or after pregnancy can predispose individuals to mood instabilities during the postpartum period [22] . Consistent with this, d KO mice showed abnormal maternal behaviors and depressive tendencies during the post-partum phase [23] . Such changes in receptor levels are considered important for maintaining normal neuronal excitability in the presence of cycling neurosteroid levels. Thus, a4 containing receptors may also be considered important in the actions of neurosteroidbased drugs.
A 2009 study by Meera et al. [24] showed that etomidate, propofol and the neurosteroid, 3a, 21-dihydroxy-5a-pregnan-20-one (THDOC) increased peak currents with GABA similarly on a4b3 and in a4b3d recombinant receptors indicating that increases in GABA efficacy are not solely due to d subunit incorporation. Evidence from other studies also supports the notion that anesthetic actions of GABA A -Rs may be determined by binding sites formed between the interface of ab subunits [25] .
Evidence supporting the role of a4 subunit-containing receptors in the actions of injectable anesthetics and neurosteroids has also been obtained from a4 KO studies. a4 KO mice were largely insensitive to cellular and behavioral responses to the sedative-hypnotic THIP [26] and were also resistant to isoflurane-induced amnesia but not immobility [27] . Similarly, the role of a4-containing receptors in the effects of neurosteroids was substantiated by cellular characterization of the a4 KO. Electrophysiological recordings from the dentate gyrus granule neurons of the hippocampus of a4 KO mice revealed markedly reduced cellular responses to the synthetic neurosteroid anesthetic, alphaxalone [28] .
Therefore, we hypothesized that a4-containing receptors play a role in the actions of etomidate, propofol and the neurosteroid, alphaxalone and sought to understand behavioral effects of these classes of drugs in the a4 KO. In the work described below, we tested this hypothesis by comparing wild type (WT) control and a4 KO mice on different behavioral endpoints in response to the injectable anesthetics etomidate, propofol and the prototypical neurosteroid drug, alphaxalone.
Methods

Subjects
The committee on animal care and use at the University of Pittsburgh approved all experimental protocols. Homozygous a4 KO and WT littermates were created by interbreeding heterozygous mice that possessed one functional and one nonfunctional copy of the GABA A -R a4 subunit allele as described previously [26] . Genotyping was performed by Southern Blot analysis of tail DNA as previously described [26] . Mice were of a mixed genetic background of C57BL/6J and Strain 129S1/X1 and belonged to the F3/4 generations. Mice were group housed, kept on a 12 h alternating light-dark cycle and allowed ad libitum access to food and water. Due to limited animal numbers, analysis of results by gender was not performed unless specified below. In most cases, cohorts of mice were naïve to drug treatment before each experiment. However, in some experiments, the same cohort of mice was subjected to two experiments but with a clearance period of at least 2 weeks between experiments. A 2-week interval between drug experiments is thought to return any transient expression changes back to baseline levels.
Drug Solutions
Etomidate (Amidate, 2 mg/ml, Hospira Inc., Lake Forest, IL, USA), propofol (Diprivan, 10 mg/ml, Astra Zeneca, Wilmington, DE, USA), and alphaxalone (Cat. No. P5052, Sigma Aldrich, St. Louis, MO, USA) were used. Alphaxalone was solubilized in 22.5 % b-hydroxycyclodextrin (HBC) (Cat. No. H107, Sigma Aldrich, St. Louis, MO, USA) and sonicated to arrive at a stock concentration of 7 mg/ml. All injections were administered intraperitoneally (i.p.) except propofol, which was administered by the retroorbital (r.o) route. The different doses of each drug were chosen based on prior experience or preliminary testing where applicable.
Anesthetic-Induced Changes in Locomotor Behavior
Alphaxalone was diluted to 1.5 mg/ml. Following preliminary testing, the locomotor stimulatory effect of alphaxalone (15 mg/kg) or vehicle (22.5 % HBC in saline) was tested by placing mice in the center of an open field 10 min after injection. The open field testing chambers were plexiglass walled arenas (43.2 cm 9 43.2 cm 9 30.5 cm) located within sound attenuating cubicles in which mouse activity was automatically tracked (Med Associates, St. Albans, VT, USA). Locomotor activity was assessed by measuring total distance covered. Anxiety-like behavior was assessed by comparing the percentage of distance traveled in the center zone over total distanced traveled. Mice that are more anxious would be expected to spend less time in the center zone compared to the periphery. The center zone was demarcated as the central square of the open field (11.25 9 11.25 cm). Both males and females were tested. Data were analyzed by two-way ANOVA with genotype and treatment as effects followed by Fisher's Protected Least Significant Difference (PLSD) post hoc tests.
With etomidate, a low dose locomotor stimulatory effect was not observed. Instead, pilot studies with numerous doses of etomidate indicated that a 3 mg/kg dose reliably produced a measurable sedative effect that could be studied using the open field setup. Etomidate was diluted with saline to a concentration of 0.3 mg/ml. The sedative effects of a 3 mg/kg dose of etomidate were evaluated for 10 min. Male mice were placed in the testing room 1 day before the experiment. On the morning of the experiment, mice were weighed, then injected with etomidate (i.p., 0.01 ml/g body weight) and placed separately in clean cages. Five minutes later, mice were placed in the open field chambers for automated recording of distance traveled over a 10 min period. Because vehicle control (i.e. saline) scores did not differ between genotypes in this assay [26] , only druginduced behavior was measured between genotypes. Data were analyzed by unpaired t test.
Recovery from Anesthetic-Induced Motor Ataxia Next, mice were tested for their ability to recover from motor ataxia induced by alphaxalone, etomidate, and propofol. All training and testing was performed on a fixed speed rotarod (Ugo Basile 7650, Varese, Italy) at 8 RPM. With each drug, the degree and duration of ataxia were expected to differ based on the pharmacologic and pharmacokinetic profile of each drug. Therefore, while the fixed speed rotarod format was chosen, the time criteria and the inter-trial duration were modified for each drug based on pilot trials. For each experiment, area under the curve (AUC) was measured as the area between baseline performance and the impairment produced by the drug over the time course of the experiment. AUC's were compared by one-way ANOVA with genotype as the main effect.
Alphaxalone
On the day of the experiment, male and female mice were subjected to training trials on a fixed speed rotarod. At least 4 training trials were administered at 10 min intervals so that mice achieved a criterion of 180 s on the rotarod. Mice that did not achieve the criterion at least three consecutive times were excluded from the assay. Alphaxalone was solubilized in 22.5 % b-hydroxycyclodextrin and injected at 50 mg/kg (i.p., 0.01 ml/g body weight). Post-injection, mice were tested every 10 min until recovery to baseline performance (180 s) was achieved.
Etomidate
Male mice were trained on the day of the test to a criterion of 120 s on fixed speed rotarod. Training trials were 20 min apart and at least 4 such trials were administered. Mice that did not achieve the criterion at least three consecutive times were excluded from the assay. Following training, etomidate was injected (i.p., 0.01 ml/g body weight) at 20 mg/kg. Mice lost their righting reflex briefly and recovered between 20 and 25 min. One KO mouse that was unimpaired with etomidate injection was excluded from the analysis. After injection, mice were tested on the rotarod every 20 min for 3 h.
Propofol
Mice of both sexes were trained on the previous day of the experiment to a criterion of 100 s. Because propofol is a short acting drug, each mouse was given at least 4 trials, spaced 5 min apart, to ensure that the task was learned. Once training was complete, mice were housed overnight in the testing room in their home cages. On the test day, mice were subjected to 2-3 trials to confirm compliance to criteria. Subjects that failed this test were excluded from the assay. Following this, propofol was administered at 25 mg/kg, (r.o.; 0.005 ml/g body weight) by diluting the clinical preparation with saline to a concentration of 5 mg/ ml. Mice briefly lost their righting reflex. Mice were placed on the rotarod at intervals of 5 min until recovery to baseline performance (100 s) was regained.
Anesthetic-Induced Loss of Righting Reflex (LORR)
Age-matched mice (8-20 weeks) of both sexes were injected with alphaxalone (70 mg/kg, i.p., 0.01 ml/g body weight,), etomidate (20 mg/kg, i.p., 0.01 ml/g body weight), or propofol (40 mg/kg, r.o., 0.004 ml/g body weight) for the LORR assay. Immediately after they lost their righting reflex, mice were placed supine on a V-shaped plexiglass trough until recovery. A heat lamp was used to ensure normothermia throughout the experiment. Endpoint of time to return of righting reflex was determined by ensuring that a mouse was able to right itself consecutively three times within 30 s. For etomidateinduced LORR, data were analyzed by two-way ANOVA with genotype and sex as main effects. For other LORR results, data were analyzed by unpaired t test.
Results
A Low Dose of Alphaxalone Has No Effect in a4 KO Mice
To understand the role of the GABA A -R a4 subunit in anesthetic-induced changes in locomotor activity, WT and KO mice were compared for response to low doses of alphaxalone (15 mg/kg) or etomidate (3 mg/kg) in an open field assay.
With alphaxalone, analysis of total distance traveled during the 10 min test period (Fig. 1a) revealed a significant main effect of treatment (two-way ANOVA; F(1,63) = 7, p \ 0.05) and genotype [F(1,63) = 4, p \ 0.05], but no interaction between treatment and genotype. Subsequent pair-wise comparisons revealed that baseline activity in response to vehicle injections did not differ between genotypes. In contrast, alphaxalone stimulated locomotor activity in WT (p \ 0.05) but not KO mice. Additionally, distance traveled by WT mice in response to alphaxalone was greater than the distance traveled by KO mice (p \ 0.05). Thus, alphaxalone produced a locomotor stimulatory effect in WT but not KO mice.
The distance covered in the center zone of the activity chambers was also compared between genotypes (Fig. 1b) . Mice that are more anxious would be expected to spend less time in the center zone compared to the periphery. This parameter is regarded as an indicator of anxiety-like behavior in rodents [29, 30] . Two-way ANOVA did not reveal an effect of treatment, genotype, or an interaction. Thus, a 15 mg/kg dose of alphaxalone altered ambulatory behavior but did not alter anxiety-like behavior on this assay.
Next, to understand if low doses of etomidate produced similar differences as alphaxalone between WT and a4 KO mice, we conducted several pilot experiments using low doses of etomidate on an open field assay. Pilot experiments revealed that a 3 mg/kg dose of etomidate produced a significant sedating effect in the open field assay. Because saline-treated mice did not differ by genotype on total distance traveled in previous experiments with this strain of mice [26] , only etomidate-treated WT and KO were tested. As shown in Fig. 1c , total distance covered in response to etomidate did not differ between genotypes.
Moderate Dose Effects of Anesthetics or of the Neurosteroid Alphaxalone are Unchanged in the a4 KO To test if the GABA A -R a4 subunit was required for the motor ataxic effects of injectable anesthetics, WT and KO mice were compared for motor impairment induced by a moderately high dose of alphaxalone (50 mg/kg), etomidate (20 mg/kg), or propofol (25 mg/kg) on a fixed speed rotarod (Fig. 2a-c, respectively) . In all experiments, a oneway ANOVA analysis of AUC for performance on rotarod with etomidate, propofol, and alphaxalone showed no differences between the genotypes.
High Dose Effects of Anesthetics or of the Neurosteroid Alphaxalone are Unchanged in the a4 KO Finally, the role of GABA A -R a4 subunit in the sedative/ hypnotic response induced by high doses of injectable anesthetics, was studied using the LORR assay. WT and KO mice were compared for the duration of LORR induced by alphaxalone (70 mg/kg), etomidate (20 mg/kg), or propofol (40 mg/kg). Responses to alphaxalone and propofol, respectively, did not differ between genotypes (Fig. 3a, c) . The duration of LORR in response to etomidate was influenced by sex (two-way ANOVA; F (1,20) = 5.4; p \ 0.05). Hence, males and females were analyzed separately (Fig. 3b) . However, genotypes did not differ in response to etomidate within either sex.
Discussion
The goal of these studies was to understand the contribution of a4-containing GABA A -Rs in mediating the behavioral effects of the injectable anesthetics alphaxalone, etomidate and propofol. Anesthetic-induced changes in locomotor activity, motor impairment, and LORR were compared between genotypes. The main finding from these studies was that KO mice were insensitive to the locomotor stimulatory effect of a low dose of alphaxalone compared to WT. All other behavioral responses measured in response to alphaxalone, etomidate and propofol did not differ between genotypes.
Neurosteroids are thought to exert their behavioral effects largely via d-containing GABA A -Rs [12, 31] . Studies of d subunit KO mice demonstrated that this subunit was required for alphaxalone-and pregnanoloneinduced LORR. Additionally, the anxiolytic and proabsence seizure effects of ganaxalone were reduced in d KO mice. However, the importance of individual a subunits for clinically relevant behavioral effects of neurosteroids has not been previously examined. It is well established that d-containing GABA A -Rs almost always include a4 or a6 subunits [12, [17] [18] [19] , although there are rare populations of d-containing receptors in specific brain regions devoid of a4 and a6 [32] . Because a6 subunitcontaining receptors are restricted to cerebellar granule cells, we hypothesized that the more widely expressed a4 receptors are key a subunits of the d-containing receptors mediating neurosteroid-induced behavioral effects. In support of this hypothesis we also previously reported that hippocampal dentate gyrus neurons from a4 KO mice showed reduced current potentiation with alphaxalone compared to WT controls [28] . Therefore, we predicted that KO of a4 would reduce behavioral sensitivity to alphaxalone.
Consistent with our hypothesis, a4 KO mice did not respond to the locomotor stimulatory effect of a low dose Fig. 1 The low dose effect of alphaxalone but not etomidate was absent in a4 KO mice. a Total distance traveled by WT and a4 KO mice in response to a low dose of alphaxalone (15 mg/kg) over a 10 min period. Genotypes did not differ in response to vehicle injection. Alphaxalone stimulated locomotor activity compared to vehicle in WT (p \ 0.05) but not KO mice. b Percent distance covered in the center zone of the open field by WT and a4 KO mice. No differences were observed between vehicle-treated and alphaxalone-treated WT and a4 KO animals. c Total distance traveled in response to a low dose of etomidate (3 mg/kg). No differences were observed between WT and KO mice. Data are expressed as mean ± SEM of alphaxalone in an open field assay. This result indicates that a4-containing receptors are critical for the low dose locomotor stimulatory effect of alphaxalone. In contrast to our expectations, the moderate/high dose effects of alphaxalone on motor incoordination and LORR were unchanged between WT and KO mice suggesting that a4-containing receptors are not required for these effects. This result is especially surprising considering the reduction in sensitivity of d subunit KO mice to neurosteroid-induced LORR.
Recent photoaffinity labeling experiments with azietomidate indicate that etomidate binds to specific amino acids at the a-b interface [12, 25] . In addition, a study comparing the effect of etomidate on recombinant a4b3 and a4b3d receptors showed that etomidate-induced enhancement was similar in both kinds of receptors [24] . Thus, increases in GABA efficacy by anesthetics are not necessarily due to the d subunit alone. Consistent with this observation, the d KO mice did not display differences in response to etomidate or propofol in LORR assays [12] . To ascertain if the a4 subunit played a role in the behavioral effect of etomidate, we compared LORR, motor ataxia and sedation between WT and KO mice. These effects were unchanged between genotypes suggesting that a4 subunits are not critical for etomidate effects on behavior. In our hands, however, a sex difference was observed within each genotype in response to etomidate-induced LORR. This result is consistent with a previous study where a1 GABA A -R subunit KO female (but not male) mice were slightly resistant to etomidate-induced LORR [33] . However, others have not observed this difference [10] . Given that these effects were observed in WT as well as a4 KO mice, we speculate that differences between sexes in response to etomidate may be a result of underlying differences in levels of circulating neurosteroids or changes in GABA A -R subunit expression across the estrus cycle [e.g., 34]. Taking into account results from a5 KO mice, where etomidate-induced LORR, motor ataxia and sedation were also unchanged between genotypes [35] , together, these data indicate that the major a subunit(s) responsible for mediating etomidate-induced LORR, motor ataxia, and sedation is likely a2, a3, and/or a6. Furthermore, since a2 and a3 frequently partner with b3 and c2 subunits to form a2b3c2 and a3b3c2 receptor subtypes, and b3 N265 M knockin mice demonstrate that b3 is required for etomidate-induced immobility and hypnosis [5] , these receptor subtypes seem most likely to mediate these effects of etomidate. Next, propofol-induced LORR and motor ataxia were compared in a4 KO and WT. Because WT and KO mice did not differ in their response to propofol, these studies indicate that a4-containing GABA A -Rs are not required for these effects of propofol. Previous work on the actions of propofol has centered on the b2 and b3 subunits. Sites N289, N290 and N265 of b2 and b3 subunits are thought to be critical for the effects of propofol through work on recombinant receptors expressed in xenopus laevis oocytes, HEK cells as well as in mutant mouse models [5, [36] [37] [38] . We previously reported that a1 KO mice were normally sensitive to propofol-induced LORR [33] . The studies reported here on a4 KO mice indicate that a4-containing GABA A -Rs are also not required for the propofol-induced motor ataxia or LORR. Further studies on a2, a3 or a6 mutant mouse models will have to be conducted to Therefore, male and females were analyzed separately. However, no differences were observed between genotypes within either sex. c Propofol (40 mg/kg)-induced LORR did not differ between genotypes. Data are expressed as mean ± SEM ascertain if actions of propofol are dependent on a particular a subunit.
A noteworthy observation from studies on GABA A -R a4 subunit KO mice, is the emerging common theme that the a4 subunit is only required for response to very low doses/ concentrations of some GABAergic drugs. a4-containing receptors have previously been referred to as the 'one glass of wine' receptors due to their unique sensitivity to low doses of ethanol [39, 40] . As reported here, a4 KO mice were less sensitive to low dose neurosteroid-induced locomotor stimulation but were normally sensitive to moderate/ high dose neurosteroid-induced motor ataxia and LORR. Similarly, for the volatile anesthetic isoflurane, a4 KO mice were substantially less sensitive to low concentrations that produced amnesia, slightly less sensitive to higher concentrations that produced LORR, and normally sensitive to very high concentrations that produced the equivalent of surgical immobility [27] . Finally, a4 KO mice were resistant to low dose ethanol-induced cognitive impairment but not to moderate/high doses of ethanol [41, 42] . Given the sensitivity of extrasynaptic a4 containing receptors to ambient levels of GABA, it is not surprising to imagine that these receptors are more readily modulated at low doses of anesthetic drugs. Higher doses of the same drugs presumably activate synaptic receptors to enforce the full effects of the drug thus rendering the contribution of GABA a4 receptors, at higher concentrations, infinitesimal. The exception to these observations is the behavioral response to the selective extrasynaptic GABA A -R agonist, gaboxadol (a.k.a. THIP) [26] . a4 KO mice were largely insensitive to even high doses of this drug. These results indicate that for many (but not all) GABAergic drugs, a4-containing GABA A -R may only be important for low dose effects.
One caveat to these studies that cannot be ignored is that the mice studied were global, constitutive KOs that may harbor alterations to compensate for the lack of a4, which may mask the normal endogenous role of a4 in behavioral responses to anesthetics. Such compensatory changes are not uncommon in response to the constitutive lack of particular receptors, as is the case with d KO mice [43] . In the a4 KO mice, as well, altered levels of other GABA A -R subunits have been observed [44] . Additionally, we have observed that while a4 KO reduces ethanol potentiation of tonic inhibition, synaptic responses to ethanol are surprisingly increased [45] . These studies are indicative of compensatory changes occurring in the a4 KO mice. However, changes in levels of all known GABA subunits in the a4 KO mice have not yet been quantified. Thus, how these and other yet to be discovered, examples of compensation in a4 KO mice impact responses to anesthetics remains to be determined.
In summary, we report that all injectable anestheticinduced behavioral responses tested were similar between WT and GABA A -R a4 subunit KO mice with the exception that KO animals were less sensitive to low dose alphaxalone-induced locomotor stimulation. Therefore, we conclude that a4-containing receptors are not required for most injectable anesthetic-induced behavioral responses, but may selectively mediate low dose responses to neurosteroid anesthetics like alphaxalone.
